Madrigal Pharmaceuticals Inc’s recently made public that its Officer and Director William John Sibold acquired Company’s shares for reported $3.3 million on Sep 09 ’25. In the deal valued at $453.80 per share,7,279 shares were bought.
Then, Sibold William John sold 7,279 shares, generating $3,243,741 in total proceeds. Upon selling the shares at $445.63, the President and CEO now owns 102,474 shares.
Before that, FRED CRAVES bought 2,900 shares. Madrigal Pharmaceuticals Inc shares valued at $1,251,896 were divested by the Former Director at a price of $431.69 per share.
A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who increased its forecast for the stock in late February from “a Neutral” to “a Buy”. H.C. Wainwright also remained covering MDGL and reiterated its “Buy” recommendation on February 27, 2025. Cantor Fitzgerald started covering the stock on June 28, 2024. It rated MDGL as “a Neutral”.
Price Performance Review of MDGL
On Friday, Madrigal Pharmaceuticals Inc [NASDAQ:MDGL] saw its stock fall -0.19% to $439.93. Over the last five days, the stock has gained 1.78%. Madrigal Pharmaceuticals Inc shares have risen nearly 88.52% since the year began. Nevertheless, the stocks have risen 42.57% over the past one year.
How much short interest is there in Madrigal Pharmaceuticals Inc?
A steep rise in short interest was recorded in Madrigal Pharmaceuticals Inc stocks on 2025-08-29, growing by 66452.0 shares to a total of 4.05 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 3.98 million shares. There was a rise of 1.64%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 11, 2024 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $382 price target.
